Ichor partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical Trial in Stage III and IV melanoma patients

SAN DIEGO, JUNE 2, 2015 -- Ichor Medical Systems, Inc. (Ichor) is pleased to announce that their partner Scancell Holdings plc (Scancell) presented updated and very encouraging data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody® being developed for the treatment of patients with melanoma, at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The trial is an open label, non-randomized study to characterize the safety and tolerability of SCIB1 administered using Ichor's TriGrid™ delivery system, as well as provide initial assessment of the ability of SCIB1 to delay or prevent disease recurrence in patients with Stage III/IV melanoma.

Among the sixteen Stage III (n=9) and Stage IV (n=7) subjects with melanoma that was resected at the time of study entry, the median of disease free and overall survival have not yet been reached. All sixteen subjects are still alive, and 11/16 have remained disease free with a median follow up duration of 34 months (range 27-46 months). In addition, the data showed that the procedure was well tolerated. The most common adverse events were injection site reactions, which were mild and transient. Overall, these results suggest that SCIB1, delivered by Ichor's TriGrid, is safe, tolerable, and may confer protection from recurrence of melanoma, with little associated toxicity.

SCIB1, the first product candidate derived from Scancell's broad Immunobody platform to enter clinical testing, is a DNA vaccine which encodes a human antibody engineered to contain multiple T cell epitopes derived from melanoma antigens. Scancell's Immunobody technology is designed to facilitate recognition of these epitopes by the patient's immune system, resulting in activation of highly potent, tumor-specific T cells, translating into an effective anti-tumor response.

Ichor's TriGrid platform, the first integrated and fully automated device for electroporation-mediated DNA administration in humans, is being used to deliver the SCIB1 DNA vaccine to overcome the suboptimal potency observed with DNA vaccines delivered by conventional injection. The TriGrid platform is being tested in clinical trials for a wide range of disease indications, and has been recently licensed by Janssen Pharmaceuticals, Inc. and Pfizer for infectious disease and oncology indications, respectively.

Robert Bernard, Ichor Founder and CEO, stated, "Ichor is excited to see that the TriGrid and SCIB1 therapy may be beneficial to these cancer patients. We are optimistic about the potential for the TriGrid to enable many more nucleic-acid based therapies to address a variety of disease areas for current and future partners."

The full Scancell press release can be found at: www.scancell.co.uk/news.

About Ichor Medical Systems, Inc.

Ichor Medical Systems' TriGrid™ Delivery System (TriGrid) is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. Ichor, a privately-held biotech company based in San Diego, CA, is collaborating with partners to provide its enabling TriGrid platform as a means for delivery of DNA drugs and vaccines in disease indications such as cancer, malaria, hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection, human immunodeficiency virus (HIV) infection, and Ebola, as well as for multiple biodefense agents. Funded by the Defense Advanced Research Projects Agency (DARPA), the TriGrid platform is also being developed for DNA-based antibody delivery as a rapid countermeasure in the event of an infectious outbreak or biological weapons attack. Visit http://www.ichorms.com.

For Further Information

Ichor Medical Systems
May D. Pidding, Ph.D.
Director, Business Development
mpidding@ichorms.com
(858) 550-2022 x104